We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current DXRX market cap is 87.43M. The company's latest EPS is GBP 0.0086 and P/E is 120.35.
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 10.37M | 13.44M | 12.7M | 13.94M | 19.5M |
| Operating Income | 1.13M | 740k | -716k | 550k | 575k |
| Net Income | 632k | 398k | 263k | 561k | 724k |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 7.81M | 22.37M | 43.52M | 45.01M | 48.26M |
| Total Liabilities | 5.18M | 2.24M | 3.28M | 4.36M | 5.74M |
| Total Equity | 2.63M | 20.13M | 40.24M | 40.65M | 42.51M |
| Year End December 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -954k | -630k | 253k | 570k | 5.1M |
| Investing | -1.11M | -2.92M | -6.29M | -5.6M | -4.76M |
| Financing | 1.05M | 13.29M | 19.61M | -270k | -191k |
| Market Cap | 87.43M |
| Price to Earnings Ratio | 120.35 |
| Price to Sales Ratio | 4.48 |
| Price to Cash Ratio | 4.41 |
| Price to Book Ratio | 2.06 |
| Dividend Yield | - |
| Shares Outstanding | 84.47M |
| Average Volume (1 week) | 102.21k |
| Average Volume (1 Month) | 80.38k |
| 52 Week Change | -1.43% |
| 52 Week High | 109.00 |
| 52 Week Low | 80.50 |
| Spread (Intraday) | 1 (0.96%) |
| Company Name | Diaceutics Plc |
| Address |
first floor, building two belfast BT9 6GW |
| Website | https://www.diaceutics.com |
| Industry | testing laboratories (8734) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
